

TISSUE BONDING AND SEALING COMPOSITION AND METHOD OF USING THE SAME

This is a continuation-in-part of Ser. No. 07/560,069, 5
filed Jul. 27, 1990, now U.S. Pat. No. 5,209,776.

FIELD OF THE INVENTION

The present invention is directed to a composition 10
adapted to bond separated tissues together or to coat
tissues or prosthetic materials to enhance strength and
water tightness preferably upon the application of en-
ergy and particularly to a composition which is acti-
vated by a laser to form a strong, biologically compati-
ble bond or coating.

BACKGROUND OF THE INVENTION

All surgical disciplines are concerned with the repair
of damaged tissues and vessels. Damage can be the
result of direct trauma to the body or as part of a surgi- 20
cal procedure in which there is a separation of normally
continuous tissue such as in vein or artery anastomoses.
Regardless of the cause, proper repair of the tissue or
blood vessel is an essential step in the positive outcome
of surgery.

The joining of separated tissues has principally been
performed by suturing or stapling in which the skilled
hands of the surgeon stitch or staple the separated tis-
sues together. This procedure not only requires signifi-
cant skill but also is a slow, tedious process, particularly 30
if extensive repair is required.

Suturing suffers from several other drawbacks which
have complicated surgical procedures. First, leaks often
develop at the ends of the joined tissues which can
require resuturing. In addition, suturing itself is a 35
trauma to the tissue which can cause additional damage
and extend the healing period. Further there are occur-
rences of inflammation in vicinity of the sutures which
can result in late failure of a repair or anastomosis.

As a result, efforts have focused on overcoming the 40
difficulties associated with suturing by the development
of sutureless repairs using surgical adhesives or glues
which adhere to tissue surfaces and form a bond there-
between.

The most common tissue adhesive is fibrin adhesive 45
or glue typically containing a concentrate of fibrinogen
and thrombin as disclosed in U.S. Pat. Nos. 4,362,567,
4,414,976 and 4,909,251 and Canadian Patent No.
1,168,982. The adhesives require mixing immediately
prior to application and react in a manner similar to the 50
last stages of the clotting cascade to form a fibrin clot.
The clot effects hemostasis, a cessation of bleeding. By
virtue of the physical properties of a blood clot, a small
amount of tensile strength is present in the clot. Fibrin
glue has been used in a variety of surgical procedures 55
for its hemostatic properties, biocompatibility and as a
modest reinforcement of the strength or more com-
monly the watertightness of a repair. (See, for example,
Dennis F. Thompson et al., "Fibrin Glue: A Review of
its Preparation, Efficacy and Adverse Effects as a Topi- 60
cal Hemostat", *Drug Intell. Clin. Pharm.* vol. 22, pp.
946-952 (1988); and Richard L. Bureson et al., "Fibrin
Adherence to Biological Tissues", *J. Surg. Res.* vol. 25,
pp. 523-539 (1978).

Fibrin adhesive, however, has significant drawbacks 65
which has prevented its commercial use in the United
States. First, in order to prepare commercial quantities
of fibrin adhesive the components must be obtained

from pooled human blood. There is therefore the possi-
bility of infection from agents such as Hepatitis "B",
HIV virus and others. Particularly in the United States,
the threat of infection has outweighed the benefits of
obtaining commercial quantities of fibrin adhesive. As a
result, the production of fibrin adhesive has been limited
to quantities obtained from a patient's own blood to
reduce the risk of infection. (See, for example, Karl H.
Siedentop et al., "Autologous Fibrin Tissue Adhesive",
Laryngoscope vol. 95, pp. 1074-1076 (September, 1985);
Gidon F. Gestring et al., "Autologous Fibrinogen for
Tissue-Adhesion, Hemostasis and Embolization", *Vasc.*
Surg. vol. 17 pp. 294-304 (1983) and D. Jackson Cole-
man et al., "A Biological Tissue Adhesive for Vi- 15
treoretinal Surgery", *Retina* vol. 8 no. 4, pp. 250-256
(1988). These autologous procedures make the use of
fibrin adhesive costly and time consuming and therefore
of limited value.

Second, fibrin glue preparations suffer from poor
tensile strength. Third, fibrin glue requires time con-
suming mixing of multiple reagents immediately prior
to application. Finally, once the reagents are mixed the
glue polymerizes, and its removal disrupts the tissue on
which it has been applied.

Non-biological materials have been tried as surgical
adhesives in an effort to reduce the risk of infection over
adhesives obtained from pooled blood. Isobutyl-2-
cyanoacrylate has been applied to separated tissues and
has formed a solid watertight seal shortly after contact
with the tissue. Khalid J. Awan et al., "Use of Isobutyl- 25
2-Cyanoacrylate Tissue Adhesive in the Repair of Con-
junctival Fistula in Filtering Procedures for Glau-
coma", *Annals of Ophth.* pp. 851-853 (August, 1974).
However, such adhesives have been criticized because
they are irritating to tissues and difficult to apply. An-
drew Henrick et al., "Organic Tissue Glue in the Clo-
sure of Cataract Incisions", *J. CATARACT REFRACT.*
SURG. vol. 13, pp. 551-553 (September, 1987).

Thus, surgical adhesives have not been successful in
replacing the suture as the primary means of tissue and
vessel repair.

Another approach to sutureless tissue repair is tissue
welding. Tissue welding involves the bonding of tissues
together using an energy source such as a laser beam.
Several types of lasers have been found useful for tissue
welding including Nd:YAG, CO₂, THC:YAG and Argon.
Julian E. Bailes et al., "Review of Tissue Welding
Applications in Neurosurgery", *Microsurgery* vol. 8, pp.
242-244 (1987); Rodney A. White et al., "Mechanism of 50
Tissue Fusion in Argon Laser-Welded Vein-Artery
Anastomoses", *Lasers in Surgery and Medicine* vol. 8,
pp. 83-89 (1988); Lawrence S. Bass et al., "Sutureless
Microvascular Anastomoses using the THC:YAG La-
ser: A Preliminary Report", *Microsurgery* vol. 10, pp.
189-193 (1989), Masame Suzuki et al., U.S. Pat. No.
4,625,724, Jude S. Sauer U.S. Pat. No. 4,633,870; Doug-
las Dew, U.S. Pat. Nos. 4,672,969 and 4,854,320, each
incorporated herein by reference.

Tissue welding has been performed on a variety of
tissues. For example, a carbon dioxide laser has been
used in nerve tissue repair as described in Julian E.
Bailes et al., *Microsurgery*. Tissue welding has success-
fully repaired intestinal tissue. Semion Rockkind et al.,
"Low-Energy CO₂ Laser Intestinal Anastomosis: An
Experimental Study" *Lasers in Surgery and Medicine*
vol. 8 pp. 579-583 (1988).

The use of lasers to directly weld tissues can eliminate
about two-thirds of the time needed to repair damaged